Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.

Abstract: A brightness compensation circuitry includes a data-setting switch unit receiving a data-setting signal, a pixel unit including a pixel driving circuit that receives the data-setting signal during a data-input period to generate a driving current, and a compensation circuit receiving the driving current generated by the pixel driving circuit. The compensation circuit controls the data-setting switch unit to conduct or not conduct by determining whether or not a magnitude of the driving current conforms with a criterion that is associated with target brightness of the pixel unit.

Abstract: A packaged IC wherein a portion of the sidewalls of the packaged IC are solderable metal. A method of forming a packaged IC wherein a portion of the sidewalls of the wire bond pads or the flip chip pads that are exposed by sawing during singulation are solderable metal. A method of forming a packaged IC wherein all of the sidewalls of the wire bond pads or the flip chip pads that are exposed by sawing during singulation are solderable metal and a portion of sidewall of the molding compound is solderable metal.

Abstract: The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.

Abstract: A virtual desktop can be remoted to a client device by transmitting a video stream using a video coding format, such as H.264, where higher resolution video can be streamed than natively supported by the encoder or decoder. The encoder framebuffer is divided into a plurality of equal size child buffers, each child buffer is assigned an identifier for identifying the child buffer. Padding pixels can be added to the child buffers to make the child buffer size acceptable for the video coding format. The child buffers are encoded using the video coding format and the encoded frames are transmitted to a client. On the decoder side, the encoded child frames are decoded, padding pixels are removed, and the data is used to update corresponding child buffers in a framebuffer on the client display system.

Abstract: The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.

Abstract: The disclosure describes multi-junction solar cell structures that include two or more graded interlayers.

Abstract: A method of lead frame surface modification includes providing at least one pre-fabricated metal lead frame or package substrate (substrate) unit including a base metal having a die pad and a plurality of contact regions surrounding the die pad. An ink including a material that is a solid or a precursor for a solid that forms a solid upon a curing step or a sintering step that removes a liquid carrier is additively deposited including onto at least one of (i) a region of the die pad and (ii) at one region of at least a first of the contact regions (first contact region). The ink is sintered or cured to remove the liquid carrier so that a substantially solid ink residue remains.

Abstract: Disclosed are antibody drug conjugates (ADC) that include highly potent toxic agents with specific antibodies to target tumors. Also disclosed are related antibodies, polypeptides, nucleic acids, host cells, compositions, and uses.

Abstract: A method of lead frame surface modification includes providing at least one pre-fabricated metal lead frame or package substrate (substrate) unit including a base metal having a die pad and a plurality of contact regions surrounding the die pad. An ink including a material that is a solid or a precursor for a solid that forms a solid upon a curing step or a sintering step that removes a liquid carrier is additively deposited including onto at least one of (i) a region of the die pad and (ii) at one region of at least a first of the contact regions (first contact region). The ink is sintered or cured to remove the liquid carrier so that a substantially solid ink residue remains.

Abstract: A bioelectronic device and method of making is disclosed. The device includes a scaffold formed via 3D printing. The device also includes a biologic and an electronic device formed via 3D printing, the biologic and electronic device being interweaved with or coupled to the scaffold. The electronic component may e.g., include at least one of hard conductors, soft conductors, insulators and semiconductors. The scaffold may be formed of at least one of synthetic polymers and natural biological polymers. The biologic may include at least one of animal cells, plant cells, cellular organelles, proteins and DNA (including RNA).

Abstract: A light sensing device includes a substrate, a plurality of light sensing elements and a cover. The plurality of light sensing elements are disposed on the substrate for sensing light. The cover is utilized for sheltering the plurality of light sensing elements, wherein the cover includes a hole for passing the light. A set of the plurality of light sensing elements is selected to be enabled according to a location of the hole relative to the plurality of light sensing elements.

Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.

Abstract: Disclosed is a process whereby diverse classes of materials can be 3D printed and fully integrated into device components with active properties. An exemplary embodiment shows the seamless interweaving of five different materials, including (1) emissive semiconducting inorganic nanoparticles, (2) an elastomeric matrix, (3) organic polymers as charge transport layers, (4) solid and liquid metal leads, and (5) a UV-adhesive transparent substrate layer, demonstrating the integrated functionality of these materials. Further disclosed is a device for printing these fully integrated 3D devices.

Abstract: Temperature and threshold parameters relating to the cooling system are received. A control condition suitable for the cooling system is determined. If the ambient temperature is lower than the first temperature threshold, the working fluid passage between the free cooling device and the system to be cooled and the working fluid passage between the free cooling device and the PCM cooling device are turned on, in addition to the PCM cooling device is set into the first working mode. If the ambient temperature, AT, is higher than the second temperature threshold and the temperature of the PCM material is lower than the melted state temperature threshold, the working fluid passage between the PCM cooling device and the system to be cooled is turned on, the working fluid passages relating to the free cooling device is turned off, and the PCM cooling device is set into the second working mode.

Abstract: A method of lead frame surface modification includes providing at least one pre-fabricated metal lead frame or package substrate (substrate) unit including a base metal having a die pad and a plurality of contact regions surrounding the die pad. An ink including a material that is a solid or a precursor for a solid that forms a solid upon a curing step or a sintering step that removes a liquid carrier is additively deposited including onto at least one of (i) a region of the die pad and (ii) at one region of at least a first of the contact regions (first contact region). The ink is sintered or cured to remove the liquid carrier so that a substantially solid ink residue remains.

Abstract: The disclosure herein describes a server-side system that dynamically enhances user experience on a remoting client device. During operation, the system monitors user inputs on the client device. When a user input involving a predetermined interaction between the user and the GUI on the client device is detected, the system alters parameters of frame encoding based on the user interaction. Frame updates transmitted to the client device during the user interaction are encoded with the altered encoding method to improve user experience. Once the user interaction is ended, the system reverts back to the normal encoding method.

Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.

Abstract: A light sensing device includes a substrate, a plurality of light sensing elements and a cover. The plurality of light sensing elements are disposed on the substrate for sensing light. The cover is utilized for sheltering the plurality of light sensing elements, wherein the cover includes a hole for passing the light. A set of the plurality of light sensing elements is selected to be enabled according to a location of the hole relative to the plurality of light sensing elements.

Abstract: The present invention relates to methods of determining the presence or absence of abnormal lymphoid cells or abnormal myeloid cells in a cell sample, with the methods comprising subjecting the cell sample to conditions that will activate any inactive matriptase present in the cell sample and measuring the levels of activated matriptase in the cell sample. Once measured, these levels can then be compared to control levels of active matriptase to determine if the cell sample has elevated levels of activated matriptase over control levels of active matriptase. An elevation in the levels of activated matriptase in the cell sample is indicative that the cell sample contains abnormal lymphoid cells or abnormal myeloid cells.